<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7464671</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics12080710</article-id><article-id pub-id-type="publisher-id">pharmaceutics-12-00710</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Insulin-Loaded Barium Salt Particles Facilitate Oral Delivery of Insulin in Diabetic Rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zaman</surname><given-names>Rahela</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0322-2058</contrib-id><name><surname>Karim</surname><given-names>Md. Emranul</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9225-3678</contrib-id><name><surname>Othman</surname><given-names>Iekhsan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zaini</surname><given-names>Anuar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chowdhury</surname><given-names>Ezharul Hoque</given-names></name><xref rid="c1-pharmaceutics-12-00710" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceutics-12-00710">Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya 47500, Malaysia; <email>rahela.zaman@monash.edu</email> (R.Z.); <email>karim604306@gmail.com</email> (M.E.K.); <email>iekhsan.othman@monash.edu</email> (I.O.); <email>anuar.zaini@monash.edu</email> (A.Z.)</aff><author-notes><corresp id="c1-pharmaceutics-12-00710"><label>*</label>Correspondence: <email>md.ezharul.hoque@monash.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>710</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Oral delivery is considered as the most preferred and yet most challenging mode of drug administration; especially a fragile and sensitive peptide like insulin that shows extremely low bioavailability through the gastro-intestinal (GIT) route. To address this problem, we have designed a novel drug delivery system (DDS) using precipitation-induced Barium (Ba) salt particles. The DDS can load insulin molecules and transport them through the GIT route. There were several in vitro simulation tests carried out to prove the efficiency of Ba salt particles as oral delivery candidates. All three Ba salt particles (BaSO<sub>4</sub>, BaSO<sub>3,</sub> and BaCO<sub>3</sub>) showed very good loading of insulin (&#x0003e;70% in all formulations) and a degree of resistance throughout a wide range of pHs from basic to acidic conditions when assessed by spectrophotometry. Particles and insulin-associated particles were morphologically assessed and characterized using FE-SEM and FT-IR. A set of tests were designed and carried out with mucin to predict whether the particles are potentially capable of overcoming one of the barriers for crossing intestinal epithelium. The mucin binding experiment demonstrated 60&#x02013;100% of mucin adhesion to the three different particles. FT-IR identifies the characteristic peaks for mucin protein, particles, and particle-mucin complex re-confirming mucin adhesion to the particles. Finally, the effectiveness of nano-insulin was tested on streptozotocin (STZ) induced diabetic rats. A short acting human insulin analog, insulin aspart, was loaded into Ba salt particles at a dose of 100 IU/Kg prior to oral administration. Among the three formulations, insulin aspart-loaded BaSO<sub>4</sub> and BaCO<sub>3</sub> particles dramatically reduced the existing hyperglycemia. BaSO<sub>4</sub> with loaded Insulin showed an onset of glucose-lowering action within 1 hr, with blood glucose level measured significantly lower compared to the 2nd and 3rd h (<italic>p</italic> &#x0003c; 0.05). Insulin-loaded BaCO<sub>3</sub> particles showed a significant decrease in blood glucose level at 1&#x02013;2 h, although the glucose level started to show a slight rise at 3rd h and by 4th h, it was back to baseline level. However, although BaSO<sub>3</sub> particles with loaded insulin showed a trend of reduction in blood glucose level, the reduction was not found to be significant (<italic>p</italic> &#x0003c; 0.05) at any point in time. Therefore, oral formulations of insulin/BaSO<sub>4</sub> and insulin/BaCO<sub>3</sub> particles were observed as effective as native insulin aspart subcutaneous formulation in terms of onset and duration of action. Further investigation will be needed to reveal bioavailability and mechanism of action of this novel Nano-Insulin formulations.</p></abstract><kwd-group><kwd>insulin</kwd><kwd>oral delivery</kwd><kwd>barium salt particles</kwd><kwd>barium phosphate</kwd><kwd>barium carbonate</kwd><kwd>barium sulfite</kwd><kwd>acidic pH</kwd><kwd>pepsin</kwd><kwd>mucin</kwd><kwd>sustained release</kwd><kwd>hyperglycemia</kwd><kwd>diabetes</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-12-00710"><title>1. Introduction</title><p>The emergence of protein therapeutics is being considered as one of the biggest milestones of 20th century medical and pharmaceutical science [<xref rid="B1-pharmaceutics-12-00710" ref-type="bibr">1</xref>]. Advancement in biotechnology and a better understanding of the pathophysiology of clinical conditions helped several protein and peptide drugs to be recognized as potential therapeutics [<xref rid="B2-pharmaceutics-12-00710" ref-type="bibr">2</xref>]. The trend is ongoing and in the next few decades, protein and peptide therapeutics will be covering an even bigger share of pharmaceutical products in industry. However, one disturbing fact for protein and peptide therapeutics is that there is a scarcity in noninvasive oral modes of administration. Proteins are naturally hydrophilic molecules with poor absorbance through the intestine and often prone to harsh pH and enzymatic degradation [<xref rid="B2-pharmaceutics-12-00710" ref-type="bibr">2</xref>]. For example, the first-ever protein molecule used as therapeutic was insulin which, since that time, has been the one and only treatment for type1 diabetes as well as for type2 diabetes mellitus [<xref rid="B1-pharmaceutics-12-00710" ref-type="bibr">1</xref>]. Yet, the only form of treatment available for insulin is the injectable form. Regular and very frequent subcutaneous (SC) administrations are associated with low patient compliance and multiple injection site injuries. Unfortunately, it is not possible to administrate insulin as an oral tablet. Insulin is a small 51 amino acid peptide molecule that is not resistant to stomach acid or enzymatic degradation.</p><p>Delivery through the oral route is generally recognized as the delivery of drugs through the GIT where the start point for a drug can be mouth or buccal and the absorption can take place from different parts of the small and large intestine [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>]. Popular searches for oral insulin are mostly restricted to direct delivery from mouth to absorption through the small intestinal wall [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-12-00710" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-12-00710" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-12-00710" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-12-00710" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-12-00710" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-12-00710" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-12-00710" ref-type="bibr">10</xref>]. The complex GI tract is one single tube intended to serve one single purpose of entry and absorbance of nutrients from an outside source and making them available to the body. The tube is divided into different organs with each organ having its own pH and enzymatic environment. For example, stomach and small intestine pH and secretary enzymes are specialized in modifying and breaking peptide and protein molecules. In this process, these organs destroy any protein drug that goes through them non-discriminatorily [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>,<xref rid="B11-pharmaceutics-12-00710" ref-type="bibr">11</xref>]. The pH and enzymes are considered a primary barrier for oral delivery of insulin and other protein drugs. Another barrier is intestinal absorption of high molecular weight protein in intact form. The intestinal wall is covered with a mucus layer which is a combination of glycoproteins and bicarbonate ions. Beneath the mucus is the epithelium, basement membrane (non-cellular layer), and a layer of submucosa that holds blood vessels and lymphatic ducts. There are different modes of uptake of molecules (phagocytosis, absorption through payer&#x02019;s patches, or endocytosis by enterocytes) depending on the size, surface charge, hydrophilic or hydrophobic nature of the molecule [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>,<xref rid="B12-pharmaceutics-12-00710" ref-type="bibr">12</xref>]. Absorption of an intact protein fails mostly due to its size and hydrophilic nature.</p><p>Despite all those setbacks, there have been several strategies proposed to design an oral protein formulation. The concept of attaching a protein molecule to another molecule that envelops and creates a cargo for it is a popular one. Nanoparticle-based strategies are best served for this concept. To be an ideal candidate for oral peptide delivery, a carrier molecule must meet few criteria, such as the ability to bind to a therapeutic molecule, showing adequate resistance to stand stomach harsh pH and enzymatic degradation and capacity to be absorbed through the intestinal wall. Due to the complexity of the task, until now the success rate in designing an oral protein formulation is still very low [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>]. A popular choice for oral insulin carriers so far included polymeric nanoparticles, like poly(lactide-co-glycolide) (PLGA) and its derivatives. Insulin incorporated into a blended polymer of poly fumaric anhydride (FA) and PLGA 50: 50 (FA: PLGA) showed a reduction of glucose load in fasted rats for 3 h [<xref rid="B4-pharmaceutics-12-00710" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-12-00710" ref-type="bibr">5</xref>]. Another formulation of HP55-coated capsule containing PLGA/RS nanoparticle- loaded insulin gradually lowered glucose level from 10&#x02013;15 h [<xref rid="B6-pharmaceutics-12-00710" ref-type="bibr">6</xref>]. Apart from PLGA particles, there were few successful oral nano-insulin delivery tools reported using chitosan (CS) and its derivatives. PH-sensitive CS particles showed a promising 15 h long effect on blood glucose levels in diabetic rats, however, the effect started with a burst release [<xref rid="B7-pharmaceutics-12-00710" ref-type="bibr">7</xref>]. Similarly, TBA (thiolated polymer 2-Iminothiolane)-attached CS with incorporated insulin showed a glucose-lowering effect for 24 h in non-diabetic rats [<xref rid="B13-pharmaceutics-12-00710" ref-type="bibr">13</xref>]. Lysosome-entrapped insulin (LEI) also reported for successful oral insulin formulation [<xref rid="B14-pharmaceutics-12-00710" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-12-00710" ref-type="bibr">15</xref>]. Despite the success of the animal model, none of the formulations were qualified for the clinical trial. Most recently, oral insulin 338(1338) has been taken out of the Phase II clinical trial, although the formulation showed a good hyperglycemic grip in patients. Oral insulin 338(1338) was created by a combination of technologies involving amino acid substitution and linking to a carrier molecule. Acylation at 1338 via 18 C fatty acid let the insulin to bind reversibly with albumin which extended its half-life in circulation, while attachment to sodium caprate enhanced the absorption. The clinical trial was discontinued based on the finding that insulin 338(1338) was effective in a very high dose which would make production cost high [<xref rid="B16-pharmaceutics-12-00710" ref-type="bibr">16</xref>]. However, insulin 338(1338) is the formulation that almost made its way to the market, with the most advanced research made in the oral insulin field to date.</p><p>Another formulation is insulin tregopil (Biocon), a human insulin analog attached to a methoxy-triethylene-glycol-propionyl moiety linked to the Lys-&#x003b2;29 amino group and formulated with sodium caporate. Administration of 10&#x02013;30-mg tablets showed promising effects on hyperglycemia. The clinical trial is ongoing and we can learn better about it in a few years. Again, the bioavailability estimated in dogs seems not very high (0.82&#x02013;0.85%) which is common for oral insulin tablets [<xref rid="B17-pharmaceutics-12-00710" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-12-00710" ref-type="bibr">18</xref>]. ORMD-0801 from Oramed was successful in the Phase1 clinical trial and currently in the Phase2 clinical trial. The formulation was prepared by attaching insulin to a permeation enhancer, soybean trypsin inhibitor, and a chelator. Pre-clinical stage bioavailability in animal study was estimated at 5&#x02013;8% [<xref rid="B17-pharmaceutics-12-00710" ref-type="bibr">17</xref>,<xref rid="B19-pharmaceutics-12-00710" ref-type="bibr">19</xref>]. The clinical trial showed a promising effect on controlling blood sugar levels without any noticeable adverse side-effect. Another formulation, Diasome, which can be given both orally and subcutaneously, is liver-targeted. The oral dosing is less effective compared to SC administration [<xref rid="B17-pharmaceutics-12-00710" ref-type="bibr">17</xref>,<xref rid="B20-pharmaceutics-12-00710" ref-type="bibr">20</xref>].</p><p>The first precipitation-based particle reported for insulin loading for oral delivery was strontium- substituted carbonate apatite which showed limited success in terms of binding and release in in vitro medium [<xref rid="B21-pharmaceutics-12-00710" ref-type="bibr">21</xref>]. Here we report a novel group of precipitation-based salt particle formulations designed in our lab, having enormous potential as cargo for oral macromolecular drug delivery. There is no harsh temperature or pH processing required during the fabrication process that can contribute to preventing protein degradation or inactivation. In our earlier studies, we reported Group 2 metal sulfate, sulfite, and carbonate as potential delivery vehicles for genetic material and micromolecular drugs to tumor tissue [<xref rid="B22-pharmaceutics-12-00710" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-12-00710" ref-type="bibr">23</xref>]. These salt particles are less immunogenic compared to viral vectors and thus considered safer. Moreover, the flexible synthesis conditions make them easily modifiable depending on the target binding molecule and mode of delivery. They have a better drug loading capacity, and the drug release profile can be controlled as well [<xref rid="B22-pharmaceutics-12-00710" ref-type="bibr">22</xref>]. In this study, we aimed to investigate their effectiveness as delivery vehicles for macromolecular peptides orally. Ba salt particles (BaSO<sub>4</sub>, BaSO<sub>3,</sub> and BaCO<sub>3</sub>) have both positive and negative charged domains conferred, respectively, by cations (Ba<sup>2+</sup>) and anions (SO<sub>4</sub><sup>2&#x02212;</sup>, SO<sub>3</sub><sup>2&#x02212;</sup>, and CO<sub>3</sub><sup>2&#x02212;</sup>). Due to heterogeneous charge distribution, these particles are capable of binding peptide molecules like insulin through electrostatic interactions. The particles were tested in vitro with excellent protein loading efficiency and release profile. They also demonstrated high resistance to withstand gastrointestinal pH and enzymatic environment along with the ability to efficiently bind mucin, indicating their potential capacity for intestinal absorption. Finally, using a short-acting human insulin analog (insulin aspart), the effectiveness of oral insulin delivery was evaluated for the three different particles in diabetic rats. Among the three candidates, BaSO<sub>4</sub> and BaCO<sub>3</sub> particles were found to dramatically reduce the existing hyperglycemia, apparently working as the native insulin Aspart subcutaneous formulation in terms of onset and duration of the action.</p></sec><sec sec-type="methods" id="sec2-pharmaceutics-12-00710"><title>2. Methodology</title><sec id="sec2dot1-pharmaceutics-12-00710"><title>2.1. Materials and Methods</title><sec id="sec2dot1dot1-pharmaceutics-12-00710"><title>2.1.1. Reagents</title><p>Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) powder was purchased from Invitrogen (Waltham, MA, USA). Hydrochloric acid (HCl) (1M), sodium hydrogen carbonate (NaHCO<sub>3</sub>), barium chloride dehydrate (BaCl<sub>2</sub>, 2H<sub>2</sub>O), sodium sulfite (Na<sub>2</sub>SO<sub>3</sub>), and mucin were bought from Sigma Aldrich. Additionally, fluorescein isothiocyanate (FITC)-labelled insulin stock (Human, recombinant, expressed in yeast, lyophilized powder) was purchased from Sigma Aldrich (St. Louis, MO, USA). HEPES (2-(4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid) and sodium carbonate (Na<sub>2</sub>CO<sub>3</sub>) were from Fisher Scientific (Waltham, MA, USA) and sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>) from Merck (Kenilworth, NJ, USA). Insulin aspart (NovoRapid<sup>&#x000ae;</sup>, Novo Nordisk, Bagsv&#x000e6;rd, Denmark) was purchased from a local pharmacy. Pepsin was purchased from Promega (Madison, WI, USA).</p></sec><sec id="sec2dot1dot2-pharmaceutics-12-00710"><title>2.1.2. Reagent Preparation</title><p>1M of BaCl<sub>2,</sub> Na<sub>2</sub>SO<sub>4</sub>, Na<sub>2</sub>SO<sub>3,</sub> and Na<sub>2</sub>CO<sub>3</sub> stock solutions were prepared by calculating the amount of the respective molecular weight of powder and dissolving them in water. All solutions were stored in 1 mL aliquots at &#x02212;20 &#x000b0;C. 100 mL of bicarbonated DMEM solution was freshly prepared by dissolving 1.35 g of DMEM powder in 95 mL pure Milli-Q water, followed by the addition of 0.37 g of sodium hydrogen carbonate (0.44 mM final concentration). The pH of the solution was then adjusted to the desired level by the addition of either 1 M HCl or 1 M NaOH. The final volume was then adjusted to 100 mL. Two mg/mL of FITC-insulin stock solution was prepared by dissolving the FITC-insulin powder into an appropriate volume of pure Milli-Q<sup>&#x000ae;</sup> water.</p></sec></sec><sec id="sec2dot2-pharmaceutics-12-00710"><title>2.2. Synthesis of Empty and Insulin-Loaded Ba Salt Particles</title><sec id="sec2dot2dot1-pharmaceutics-12-00710"><title>2.2.1. Synthesis of Particles by Precipitation Reaction</title><p>Each type of Ba salt particle (BaSO<sub>4</sub>, BaSO<sub>3</sub>, or BaCO<sub>3</sub>) was prepared by incorporating a volume of cation-providing BaCl<sub>2</sub> salt into either a volume of HEPES-buffered solution (pH adjusted to 8.0) or milliQH<sub>2</sub>O and mixing the resultant solution with a volume of one anion-providing salt, Na<sub>2</sub>SO<sub>4</sub>, Na<sub>2</sub>SO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub>, respectively. The final mixture was incubated for 30 min at 37 &#x000b0;C and subsequently added to miliQH<sub>2</sub>O to obtain the final volume of particle suspension. <xref rid="pharmaceutics-12-00710-t001" ref-type="table">Table 1</xref> shows the various concentrations of reacting salts used to fabricate three different Ba salt particles. <xref ref-type="fig" rid="pharmaceutics-12-00710-f001">Figure 1</xref> is a diagrammatic representation of precipitation reaction.</p></sec><sec id="sec2dot2dot2-pharmaceutics-12-00710"><title>2.2.2. Insulin Loading into Ba Salt Particles</title><p>Each type of Ba salt particle was prepared by incorporating a volume of cation- providing BaCl<sub>2</sub> salt into either a volume of HEPES-buffered solution (pH adjusted to 8.0) or miliQH<sub>2</sub>O and mixing the solution with a volume of one anion-providing salt, Na<sub>2</sub>SO<sub>4</sub>, Na<sub>2</sub>SO<sub>3,</sub> and Na<sub>2</sub>CO<sub>3</sub>. Insulin was introduced right before addition of the 2nd salt to the medium. The final mixture was incubated for 30 min at 37 &#x000b0;C and subsequently added to milliQH<sub>2</sub>O to obtain the final volume of particle suspension. <xref rid="pharmaceutics-12-00710-t002" ref-type="table">Table 2</xref> below shows the various concentrations of reacting salts and insulin used for the preparation of insulin-loaded Ba salt particles. <xref ref-type="fig" rid="pharmaceutics-12-00710-f002">Figure 2</xref> shows a simplified diagrammatic depiction of insulin loading into particles.</p></sec></sec><sec id="sec2dot3-pharmaceutics-12-00710"><title>2.3. Characterization and Morphological Screening of Ba Salt Particles</title><sec id="sec2dot3dot1-pharmaceutics-12-00710"><title>2.3.1. Fourier Transform Infrared Spectroscopy (FT-IR)</title><p>A volume of 250 &#x000b5;L of 1M of BaCl<sub>2</sub> was taken in a centrifuge tube<sub>,</sub> followed by the addition of 100 &#x000b5;L of 1M Na<sub>2</sub>SO<sub>4</sub> or Na<sub>2</sub>SO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub> to the respective tubes to prepare BaSO<sub>4</sub>, BaSO<sub>3</sub>, or Ba<sub>2</sub>CO<sub>3</sub> particles. The samples were then incubated at 37 &#x000b0;C for 30 min. The final volume of the particle solution was made to 50 mL with the addition of milliQH<sub>2</sub>O. Samples were then centrifuged for 15 min at RPM 5000. Precipitates were separated from supernatant, stored sequentially at &#x02212;20 &#x000b0;C overnight, and at &#x02212;80 &#x000b0;C for 0.5 h and finally placed into a freeze-dryer (Labconco freeze dryer, Kansas City, MO, USA) for 5 h. Samples were read using a Varian FT-IR (Santa Clara, CA, USA) and analyzed with Resolution Pro 640 software.</p></sec><sec id="sec2dot3dot2-pharmaceutics-12-00710"><title>2.3.2. Elemental Analysis of Particles by Energy Dispersive X-Ray Spectroscopy (EDX)</title><p>5 &#x000b5;L of cation- providing salt was added to 20 &#x000b5;L milliQH<sub>2</sub>O, followed by the addition of 2 &#x000b5;L of anion-providing salt. After 30 min of incubation at 37 &#x000b0;C, 1 mL of Milli-Q H<sub>2</sub>O was added. 2 &#x000b5;L of the solution containing the particles was transferred on a coverslip. The coverslip was then air-dried in elevated temperature (45 &#x000b0;C) inside a dryer for 1 h. The dried sample was marked with a circular line with a marker for easy identification under a microscope. Samples were then subjected to platinum sputtering for 45 s with 30 mA and a factor of 2.3. Visualizations and documentation were done using a Field Emission Scanning Electron Microscope (FE-SEM) (Hitachi/SU8010, Tokyo, Japan) at 5.0 kv.</p></sec></sec><sec id="sec2dot4-pharmaceutics-12-00710"><title>2.4. Particle Stability Assessment</title><p>Ba salt particles were prepared as stated in the particle preparation <xref ref-type="sec" rid="sec2dot2dot1-pharmaceutics-12-00710">Section 2.2.1</xref>. After 30 min of incubation at 37 &#x000b0;C, 1 mL of DMEM of different pHs (pH 7.78 to pH 1.78) was added and kept at 37 &#x000b0;C. Samples were prepared in triplicates and measured at 320 nm at different time points over a period of 3 h.</p></sec><sec id="sec2dot5-pharmaceutics-12-00710"><title>2.5. Insulin Loading Efficiency of Ba Salt Particles</title><sec id="sec2dot5dot1-pharmaceutics-12-00710"><title>2.5.1. Insulin Loading Efficiency of Ba Salt Particles and Subsequent Release of Insulin from Particles at a Wide Range of pHs</title><p>FITC-insulin-loaded Ba salt particles were prepared as stated in <xref ref-type="sec" rid="sec2dot2dot2-pharmaceutics-12-00710">Section 2.2.2</xref>. After 30 min of incubation at 37 &#x000b0;C, 200 &#x000b5;L of DMEM prepared at different pHs (pH 7.78 to pH 1.78) was added. After incubation at room temperature for 10 min, the samples were centrifuged at 6000 rpm for 2 min at 4 &#x000b0;C. The supernatant was discarded and the resultant pellet was washed with 50 &#x000b5;L of HEPES, 2X. At the end of washing the supernatant was again discarded and the pellet carrying insulin-bound particles was re-suspended with 200 &#x000b5;L of 10 mM EDTA.</p><p>200 &#x003bc;L of supernatant was carefully transferred into a black 96-well plate (PerkinElmer Opti-Plate&#x02122;-96 F, Waltham, MA, USA) and fluorescence intensity values were recorded using a fluorescence microplate reader (PerkinElmer Victor X5 2030 Multi-label Reader, (Waltham, MA, USA) set with excitation/emission filters at 485 nm/535 nm wavelengths.</p><p>A standard curve was prepared from absorbance values for known amounts of free FITC-Insulin (0, 400, 800, 1200, 1600, 2000, 4000 &#x003b7;g) added to DMEM. % loading at pH 7.78 was calculated from the formula given below.
<disp-formula id="FD1-pharmaceutics-12-00710"><label>(1)</label><mml:math id="mm1"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mi>loading</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>FITC</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>Insulin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>conc</mml:mi></mml:mrow><mml:mo>.</mml:mo><mml:mrow><mml:mi>in</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pellet</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mi>conc</mml:mi><mml:mo>.</mml:mo><mml:mrow><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>added</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>FITC</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>Insulin</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>
% release at subsequent pHs (7.18&#x02013;1.78) was calculated by subtracting the amount of FITC-Insulin found in the pellet from the amount of FITC-Insulin added initially and finally, multiplying by 100.
<disp-formula id="FD2-pharmaceutics-12-00710"><label>(2)</label><mml:math id="mm2"><mml:mrow><mml:mrow><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mo>%</mml:mo><mml:mi>release</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>Insulin</mml:mi><mml:mtext>&#x000a0;</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mi>FITC</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mi>Insulin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>conc</mml:mi><mml:mo>.</mml:mo><mml:mi>in</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pellet</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>synthesized</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>at</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pH</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mn>7.78</mml:mn><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mi>FITC</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mi>Insulin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>conc</mml:mi><mml:mo>.</mml:mo><mml:mi>in</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pellet</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>particles</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>synthesized</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>at</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>subsequent</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pH</mml:mi><mml:mo>)</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mi>FITC</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mi>Insulin</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mi>conc</mml:mi><mml:mo>.</mml:mo><mml:mi>in</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pellet</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>NP</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>synthesized</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>at</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pH</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mn>7.78</mml:mn></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot5dot2-pharmaceutics-12-00710"><title>2.5.2. Morphological Assessment of Empty and Insulin-Loaded Particles by FE-SEM</title><p>The Ba salts particles were similarly prepared as described in the earlier <xref ref-type="sec" rid="sec2dot3dot2-pharmaceutics-12-00710">Section 2.3.2</xref> for FE-SEM and EDX analysis (<xref ref-type="sec" rid="sec2dot3dot2-pharmaceutics-12-00710">Section 2.3.2</xref>). Insulin-loaded particles were prepared separately (as stated in <xref ref-type="sec" rid="sec2dot2dot2-pharmaceutics-12-00710">Section 2.2.2</xref>). Visualization and documentation were done using FE-SEM (Hitachi/SU8010, Tokyo, Japan) at 2.0 kv.</p></sec></sec><sec id="sec2dot6-pharmaceutics-12-00710"><title>2.6. Assessment of Adhesion of Ba Salt Particles to Mucin</title><sec id="sec2dot6dot1-pharmaceutics-12-00710"><title>2.6.1. Spectrophotometric Analysis of Particle Adhesion to Mucin</title><p>Ba salt particles were prepared as stated in the particle preparation <xref ref-type="sec" rid="sec2dot2dot1-pharmaceutics-12-00710">Section 2.2.1</xref>. 200 &#x000b5;L of milliQH<sub>2</sub>O was added followed by the addition of 100 &#x000b5;L of mucin (3 g/L). The mixture was then incubated at 37 &#x000b0;C for 10 min followed by centrifugation at RPM13, 200 for 5 min. The supernatant was collected in a fresh tube. 250 &#x000b5;L of Bradford agent was directly added to the tube. The mixture was then incubated for 5 min before transferring it to the 96 well microplates. Absorbance was read at 595 nm using victor X5 spectrophotometer (PerkinElmer, Waltham, MA, USA). A standard curve was created using a series of different concentrations of mucin solution of 25 to 600 &#x000b5;g, mixed with 250 &#x000b5;L of Bradford agent. An unknown amount of mucin present in supernatant was calculated from the standard curve. % adhesion of particle to mucin was then calculated from added mucin with the two-step formula below:<disp-formula id="FD3-pharmaceutics-12-00710"><label>(3)</label><mml:math id="mm3"><mml:mrow><mml:mrow><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:mi>Mucin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>bound</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>to</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>Particles</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi>mucin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>present</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>in</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>the</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>pallet</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&#x02003;</mml:mo><mml:mo>&#x02003;</mml:mo><mml:mo>&#x02003;</mml:mo><mml:mo>&#x02003;</mml:mo><mml:mo>&#x02003;</mml:mo><mml:mo>&#x02003;</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi>added</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>mucin</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>mucin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>from</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>supernatant</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD4-pharmaceutics-12-00710"><label>(4)</label><mml:math id="mm4"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>adhesion</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi>mucin</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>bound</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>to</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>particles</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mi>added</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>mucin</mml:mi><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot6dot2-pharmaceutics-12-00710"><title>2.6.2. Assessment of Particle Adhesion to Mucin Using FT-IR</title><p>Samples were prepared in bigger volumes for this experiment. 250 &#x000b5;L of 1M of BaCl<sub>2</sub> in a 50 mL tube was mixed with 100 &#x000b5;L of 1M Na<sub>2</sub>SO<sub>4</sub> or Na<sub>2</sub>SO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub> to prepare BaSO<sub>4</sub>, BaSO<sub>3</sub>, or Ba<sub>2</sub>CO<sub>3</sub> particle. The samples were then incubated at 37 &#x000b0;C for 30 min. Sample tubes were then topped up to 25 mL with the addition of milliQH<sub>2</sub>O, followed by the addition of a solution containing 5 mL of mucin (3g/L). Samples were then centrifuged for 15min at 5000 RPM. Precipitates were then stored at &#x02212;20 &#x000b0;C overnight, followed by storing at &#x02212;80 &#x000b0;C for 0.5 h and freeze-drying (Labconco freeze dryer, Kansas City, MO, USA) for 5 h. Varian FT-IR (Santa Clara, CA, USA) and Varian Resolution Pro 640 software (Santa Clara, CA, USA) were used to check the spectra of particles alone, particle-mucin complexes, and mucin alone.</p></sec></sec><sec id="sec2dot7-pharmaceutics-12-00710"><title>2.7. Administration of Insulin-Loaded Particles to Diabetic Animals and Management of Hyperglycemia</title><sec id="sec2dot7dot1-pharmaceutics-12-00710"><title>2.7.1. Induction of Diabetes in Rats with Streptozotocin (STZ)</title><p>Animal experiments were conducted in accordance with the approved Animal ethics by Monash Animal Ethics Committee (MUM/2018/13). 8&#x02013;12 weeks-old male healthy Wister Kyoto rats (WKY) were subjected to intraperitoneal (IP) injection of STZ (65 mg/kg). A fraction of the rats developed hyperglycemia with a persistent high level of peripheral blood glucose (&#x02265;13 mM) within a week or two. Glucose levels in the blood (collected via tail vein) were measured using a glucometer (Terumo, Hatagaya, Shibuya-ku, Japan). The rats that didn&#x02019;t develop diabetes with 1st injection were given a 2nd IP dose of 65 mg/kg STZ.</p></sec><sec id="sec2dot7dot2-pharmaceutics-12-00710"><title>2.7.2. Effect of Orally Administrated Insulin-Loaded Particles on Hyperglycemia</title><p>Rats showing a clear sign of diabetes (peripheral blood glucose level of &#x02265;13 mM) were divided into different control and treatment groups. Each group consists of three animals. After taking a baseline blood glucose reading, each rat was given Insulin aspart-loaded Ba salt formulations via oral gavage. Rats from the control group were kept untreated (negative control), whereas rats from the positive control group received a solution containing free insulin (100 IU/kg). Treatment groups received 500 &#x000b5;L of the solution containing insulin-loaded particles (BaSO<sub>4</sub>, BaSO<sub>3</sub>, or BaCO<sub>3</sub> particles) by gavage. Blood glucose was read at regular time intervals (0.5 h, 1 h, 2 h, 3 h, and 4 h).</p><p>Blood glucose level at &#x0201c;0&#x0201d; h is the baseline blood glucose reading taken right before oral delivery of insulin-loaded particles. % reduction at any given point of time was calculated from baseline blood glucose level using the below formula,
<disp-formula id="FD5-pharmaceutics-12-00710"><label>(5)</label><mml:math id="mm5"><mml:mrow><mml:mrow><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:mi>reduction</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>blood</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>glucose</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>level</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi>baseline</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>blood</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>glucose</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>read</mml:mi></mml:mrow><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mrow><mml:mi>blood</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>glucose</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>reading</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>at</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>any</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>point</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>of</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>time</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mi>baseline</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>blood</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>glucose</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>level</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot7dot3-pharmaceutics-12-00710"><title>2.7.3. Statistical Analysis</title><p>The <italic>p</italic>-value was calculated by applying one-way ANOVA to confirm any significant reduction of blood glucose level compared to pre-treatment baseline blood glucose level, at any point in time after treatment.</p></sec></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-12-00710"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-12-00710"><title>3.1. Chemical Characterization and Morphological Analysis of Synthesized Ba Salt Particles</title><sec id="sec3dot1dot1-pharmaceutics-12-00710"><title>3.1.1. Fourier Transform Infrared Spectroscopy (FT-IR)</title><p>FT-IR was used to confirm the formation of Ba salt particles (BaSO<sub>4</sub>/BaSO<sub>3</sub>/BaCO<sub>3</sub>) by revealing the functional groups. <xref ref-type="fig" rid="pharmaceutics-12-00710-f003">Figure 3</xref> displays the FT-IR spectrum obtained for three different Ba salt particles. IR spectrum for BaSO<sub>4</sub> (<xref ref-type="fig" rid="pharmaceutics-12-00710-f003">Figure 3</xref>a) shows peaks at 1188 cm<sup>&#x02212;1</sup>, 1060 cm<sup>&#x02212;1,</sup> and 982 cm<sup>&#x02212;1</sup> which are attributed to symmetric stretching of SO<sub>4</sub><sup>2&#x02212;</sup>, peaks at 1635 cm<sup>&#x02212;1</sup> due to stretching vibration of SO<sub>4</sub><sup>2&#x02212;</sup> and peaks at 604 cm<sup>&#x02212;1</sup> and 637 cm<sup>&#x02212;1</sup>, representing out-of-plane bending for SO<sub>4</sub><sup>2&#x02212;</sup>. Peaks at 2360 cm<sup>&#x02212;1</sup> seem to be the overtone of S-O vibration [<xref rid="B24-pharmaceutics-12-00710" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-12-00710" ref-type="bibr">25</xref>]. The existence of the functional group suggests the generation of BaSO<sub>4</sub> particles. <xref ref-type="fig" rid="pharmaceutics-12-00710-f003">Figure 3</xref>b shows the characteristic peaks for SO<sub>3</sub><sup>2&#x02212;</sup> found at 490 cm<sup>&#x02212;1</sup>, 630 cm<sup>&#x02212;1</sup>, 912 cm<sup>&#x02212;1</sup>, and 1133 cm<sup>&#x02212;1</sup> position, suggesting the formation of BaSO<sub>3</sub> particles [<xref rid="B26-pharmaceutics-12-00710" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-12-00710" ref-type="bibr">27</xref>]. The characteristic peaks for CO<sub>3</sub><sup>2&#x02212;</sup> found at 855 cm<sup>&#x02212;1</sup> and 692 cm<sup>&#x02212;1</sup> (<xref ref-type="fig" rid="pharmaceutics-12-00710-f003">Figure 3</xref>c) were owing to in-plane and out-of-plane bending, whereas the peak at 1414 cm<sup>&#x02212;1</sup> corresponds with asymmetric stretching of C&#x02013;O bond and peak at 1059 cm<sup>&#x02212;1</sup> is attributed to the symmetric C&#x02013;O stretching vibration [<xref rid="B28-pharmaceutics-12-00710" ref-type="bibr">28</xref>], thus indicating the formation of BaCO<sub>3</sub> particles.</p></sec><sec id="sec3dot1dot2-pharmaceutics-12-00710"><title>3.1.2. Element Analysis of Ba Salt Particles by Energy Dispersive X-ray Spectroscopy (EDX)</title><p>EDX was carried out for elemental analysis of Ba salt particles (<xref ref-type="fig" rid="pharmaceutics-12-00710-f004">Figure 4</xref>). The presence of the desired elements in the samples would confirm the formation of the respective particles. Elemental analysis of BaSO<sub>4</sub> (<xref ref-type="fig" rid="pharmaceutics-12-00710-f004">Figure 4</xref>a) and BaSO<sub>3</sub> (<xref ref-type="fig" rid="pharmaceutics-12-00710-f004">Figure 4</xref>b) shows the presence of Ba, S, and O, whereas analysis of BaCO<sub>3</sub> confirms the presence of Ba, C, and O (<xref ref-type="fig" rid="pharmaceutics-12-00710-f004">Figure 4</xref>c).</p></sec></sec><sec id="sec3dot2-pharmaceutics-12-00710"><title>3.2. Particle Stability Assessment</title><p>One of the biggest challenges in oral delivery is pre-systemic degradation due to harsh pH in the stomach having a fluctuating pH which can be extremely acidic (~pH 1) in fasting state. Therefore, any oral delivery agent needs to be resistant to extreme acidic pH to survive during GIT transport. To test how stable Ba salt particles are in different pHs, a set of in vitro experiments were designed and carried out by exposing the formulations to a wide range of pHs for a period of 3 h.<xref ref-type="fig" rid="pharmaceutics-12-00710-f005">Figure 5</xref> shows changes in the turbidity pattern at 320 nm for Ba salt particles. Both BaSO<sub>4</sub> and BaSO<sub>3</sub> particles demonstrated much higher absorbance than BaCO<sub>3</sub> particles when measured immediately after their generation at pH 7.78, reflecting the tendency of BaSO<sub>4</sub> and BaSO<sub>3</sub> to generate a significantly higher number of particles than BaCO<sub>3</sub>. Consistently high turbidity values for BaSO<sub>4</sub> particles indicate their excellent resistance to degradation over a wide range of pHs at different time points (1&#x02013;3 h), while the turbidity of BaSO<sub>3</sub> particles sharply dropped at pH 1.69 suggesting the considerable amount of particle loss. BaCO<sub>3</sub> maintained almost the same level of turbidity throughout the range of pHs, with apparently no significant particle loss at low pH.</p></sec><sec id="sec3dot3-pharmaceutics-12-00710"><title>3.3. Insulin Loading of Ba Salt Particles</title><sec id="sec3dot3dot1-pharmaceutics-12-00710"><title>3.3.1. Insulin Loading Efficiency of Ba Salt Particles and Subsequent Release of Insulin from Particles at a Wide Range of pHs</title><p>The affinity of insulin molecules towards different Ba salt particles was assessed by separating FITC-conjugated insulin-loaded particles from free fluorescent insulin by centrifugation. Fluorescence intensity was measured at 485 nm/535 nm (excitation/emission) wavelengths. The amount of FITC-insulin present in the pellet was calculated from the standard curve prepared with a known amount of FITC-insulin vs. respective absorbance. <xref ref-type="app" rid="app1-pharmaceutics-12-00710">Supplementary Figure S1</xref> shows the standard curve prepared with free FITC-insulin. % loading was calculated by dividing the amount of FITC-insulin present in the pellet with the amount initially added and then multiplying with 100. <xref ref-type="fig" rid="pharmaceutics-12-00710-f006">Figure 6</xref>a shows % of insulin binding to three different Ba salt particles, with BaCO<sub>3</sub> particles demonstrating a higher binding affinity for insulin (100%) than BaSO<sub>4</sub> and BaSO<sub>3</sub> particles. The equations used to calculate the % of loading and % of release of insulin were shown in <xref ref-type="fig" rid="pharmaceutics-12-00710-f006">Figure 6</xref>b. FITC-insulin-loaded particles were exposed to a wide range of pHs, and as shown in <xref ref-type="fig" rid="pharmaceutics-12-00710-f006">Figure 6</xref>c, nearly 20%, 50%, and 60% of insulin were released from BaSO<sub>4</sub>, BaCO<sub>3</sub>, and BaSO<sub>3</sub> particles, respectively, when the respective insulin-particle complexes were exposed to pH of 2.47, whereas at a pH of 1.78, only around 30% of insulin was released from BaSO<sub>4</sub> and approximately 80% of insulin was released from BaSO<sub>3</sub> particles.</p></sec><sec id="sec3dot3dot2-pharmaceutics-12-00710"><title>3.3.2. Morphological Analysis of Ba Salt Particles by FE-SEM</title><p>FE-SEM analysis was carried out to study the particle morphology with respect to particle size, shape, and aggregation pattern with and without insulin loading into the particles. <xref ref-type="fig" rid="pharmaceutics-12-00710-f007">Figure 7</xref> shows micrographs for 3 different types of Ba salt particles. (a) BaSO<sub>4</sub> particles possessed distinctive irregular, oval to hollow rounder shape, with the bigger particles having oval to hollow rounder shape with particle size between 110&#x02013;200 nm and the smaller ones being irregularly shaped with particle size between 30&#x02013;100 nm. (b) BaSO<sub>3</sub> particles also had the prominent distribution of big (90&#x02013;270 nm) and very small (15&#x02013;40 nm) sized particles. The particles were found to be rounder shaped and held in tight baseball-shaped clusters with a rough surface area. Each distinctive particle cluster ranged from 500 nm to 1.0 &#x000b5;m size in diameter. Bigger particles displayed rounder shape morphology with smooth surface area, without forming a cluster (c) BaCO<sub>3</sub> particles demonstrated distinctive square to rectangular shaped morphology, with the particle size varying widely from 50 to 500 nm. Particles were closely aggregated with one another, forming rod/filament-like structures.</p></sec></sec><sec id="sec3dot4-pharmaceutics-12-00710"><title>3.4. Analysis of Effect of Insulin Loading into Particles by FE-SEM</title><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f008">Figure 8</xref>, <xref ref-type="fig" rid="pharmaceutics-12-00710-f009">Figure 9</xref> and <xref ref-type="fig" rid="pharmaceutics-12-00710-f010">Figure 10</xref> show the scanning electron microscopy images of empty Ba salt particles and insulin-loaded particles placed side-by-side to observe any morphological changes in the context of size, shape, and aggregation patterns as a result of insulin loading.</p><sec id="sec3dot4dot1-pharmaceutics-12-00710"><title>3.4.1. Effect of Insulin Loading into Baso<sub>4</sub> Particles: Changes in Morphology and Aggregation Pattern</title><p>Insulin was loaded into BaSO<sub>4</sub> particles in varying amounts. Loading of insulin altered the shape of the particles, with different concentrations of insulin showing a different degree of structural changes in particle morphology (<xref ref-type="fig" rid="pharmaceutics-12-00710-f008">Figure 8</xref>).</p><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f008">Figure 8</xref>a shows that free BaSO<sub>4</sub> particles are of rounder shape with a distinctive hollow structure in the middle and a smooth outer surface. <xref ref-type="fig" rid="pharmaceutics-12-00710-f008">Figure 8</xref>b shows BaSO<sub>4</sub> particles prepared with 2 &#x000b5;g of initially added insulin, giving the impression of free particles residing with insulin-loaded particles which were morphologically different from the empty particles. Insulin-loaded particles are baseball-shaped with a rough surface area and without a hollow structure. <xref ref-type="fig" rid="pharmaceutics-12-00710-f008">Figure 8</xref>c,d show insulin-loaded BaSO<sub>4</sub> particles prepared with 10 &#x000b5;g and 50 &#x000b5;g of insulin. With increasing insulin concentrations, the particle looked more elongated-shaped and the surface area appeared rougher. Interestingly, there was no empty BaSO<sub>4</sub> particle visualized in a high concentration of insulin.</p><p>Different amounts of insulin loading show different degrees of structural changes in particle morphology. (<bold>a</bold>) Free particles were of rounder shape with a distinctive hollow structure in the middle and a smoother outer surface. (<bold>b</bold>) A low amount of insulin (2 &#x000b5;g) added prior to particle formation showed the presence of characteristic free particles along with few insulin-loaded particles with a distinctive change in morphology. (<bold>c</bold>) and (<bold>d</bold>) Insulin-loaded particles prepared with 10 &#x000b5;g and 50 &#x000b5;g of initially added insulin. With an increasing amount of insulin, particles became more oval-shaped and the surface area looked rougher. Pictures were taken at 2.0 kV.</p></sec><sec id="sec3dot4dot2-pharmaceutics-12-00710"><title>3.4.2. Effect of Insulin Loading into Baso<sub>3</sub> Particles: Change in Morphology and Aggregation Pattern</title><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f009">Figure 9</xref> shows morphological features of empty and insulin (FITC-insulin)-loaded BaSO<sub>3</sub> particles. There were no noticeable changes in size, shape, or surface morphology of a single particle. However, a very distinctive change in aggregation pattern was observed. Empty particles tended to get clumped together, whereas insulin-loaded particles looked much less aggregated, with their clusters clearly oval shaped.</p></sec><sec id="sec3dot4dot3-pharmaceutics-12-00710"><title>3.4.3. Effect of Insulin Loading into Baco<sub>3</sub> Particles: Changes in Morphology and Aggregation Pattern</title><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f010">Figure 10</xref> shows morphological features of empty and insulin-loaded BaCO<sub>3</sub> particles with no noticeable changes in size, shape, and surface morphology of individual particles. However, very distinctive patterns in the aggregation pattern could be observed. Free particles tended to get clumped together, whereas insulin-loaded particles looked much less aggregated.</p></sec></sec><sec id="sec3dot5-pharmaceutics-12-00710"><title>3.5. Assessment of Mucin Adhesion to Ba Salt Particle</title><p>In vitro tests were done to determine the affinity of different Ba salt particles for mucin to predict whether the particles would be capable of crossing the intestinal lining. The data from the FT-IR analysis would indicate any possible interactions of mucin molecules with the particles. Mucin adhesion to the particles was further assessed by the spectrophotometric protein quantification method.</p><sec id="sec3dot5dot1-pharmaceutics-12-00710"><title>3.5.1. Analysis of Mucin Adhesion to Ba Salt Particles Using FT-IR</title><p>FT-IR was used to confirm the mucin binding of Ba salt particles (BaSO<sub>4</sub>/BaSO<sub>3</sub>/BaCO<sub>3</sub>) by revealing the functional groups for particle along with mucin protein. Samples for particles only, mucin only, and particles adhered to mucin were analyzed with FT-IR. The comparison of the peak patterns showed positive mucin binding for all three Ba salt particles. Free mucin displayed characteristic peaks of N-H at 3279 cm<sup>&#x02212;1</sup>, Amide I at 1634 cm<sup>&#x02212;1</sup>, Amide II at 1549 cm<sup>&#x02212;1</sup>, C-H at 1434 cm<sup>&#x02212;1</sup>, and 1374 cm<sup>&#x02212;1</sup>, Amide III 1232 cm<sup>&#x02212;1</sup>, C&#x02013;O&#x02013;C at 1115 cm<sup>&#x02212;1</sup> and C&#x02013;C&#x02013;O at 1029 cm<sup>&#x02212;1</sup> [<xref rid="B29-pharmaceutics-12-00710" ref-type="bibr">29</xref>]. <xref ref-type="fig" rid="pharmaceutics-12-00710-f011">Figure 11</xref>a reveals FT-IR spectrum of BaSO<sub>4</sub> particles alone, free mucin, and BaSO<sub>4</sub> particle-mucin complexes. BaSO<sub>4</sub> particles showed 8 characteristic peaks as described in an earlier <xref ref-type="sec" rid="sec3dot1dot1-pharmaceutics-12-00710">Section 3.1.1</xref>. On the other hand, mucin displayed 8 characteristic peaks (as found in the free mucin sample). Mucin-adhered BaSO<sub>4</sub> particles demonstrated 12 distinctive peaks, with peaks 2360 cm<sup>&#x02212;1</sup>, 1188 cm<sup>&#x02212;1</sup>, 1064 cm<sup>&#x02212;1</sup>, 982 cm<sup>&#x02212;1</sup>, 635 cm<sup>&#x02212;1</sup>, and 605 cm<sup>&#x02212;1</sup> matching the peaks of BaSO<sub>4</sub> particles in the similar positions. The peak at 3415 cm<sup>&#x02212;1</sup> showed a deviation to 2392 cm<sup>&#x02212;1</sup> probably due to mucin attachment to the particles. Similarly, mucin peaks at 3279 cm<sup>&#x02212;1</sup>, 1549 cm<sup>&#x02212;1</sup>, and 1434 cm<sup>&#x02212;1</sup> seemed to be shifted to 3275 cm<sup>&#x02212;1</sup>, 1539 cm<sup>&#x02212;1</sup>, and 1439 cm<sup>&#x02212;1</sup> respectively in mucin-attached particles. The existence of characteristic peaks for BaSO<sub>4</sub> and mucin indicates interactions between BaSO<sub>4</sub> particles to mucin.</p><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f011">Figure 11</xref>b shows the FI-IR spectrum for free BaSO<sub>3</sub> particles, free mucin, and BaSO<sub>3</sub>-mucin complex. BaSO<sub>3</sub> particles possess 4 characteristic peaks as described in the previous <xref ref-type="sec" rid="sec3dot1dot1-pharmaceutics-12-00710">Section 3.1.1</xref>. On the other hand, mucin has 8 characteristic peaks (as shown in the free mucin sample). Mucin-adhered BaSO<sub>3</sub> particles showed 13 distinctive peaks. The peaks of BaSO<sub>3</sub> particles, 1133 cm<sup>&#x02212;1</sup>, 912 cm<sup>&#x02212;1</sup>, 630 cm<sup>&#x02212;1</sup> and 409 cm<sup>&#x02212;1</sup> were found at 1131 cm<sup>&#x02212;1</sup>, 919 cm<sup>&#x02212;1</sup>, 509 cm<sup>&#x02212;1</sup>, and 474 cm<sup>&#x02212;1</sup> positions in mucin-adhered BaSO<sub>3</sub> particles. On the other hand, 8 characteristic peaks from mucin were found at 3311 cm<sup>&#x02212;1</sup>, 1648 cm<sup>&#x02212;1</sup>, 1539 cm<sup>&#x02212;1</sup>, 1434 cm<sup>&#x02212;1</sup>, 1298 cm<sup>&#x02212;1</sup>, 1343 cm<sup>&#x02212;1</sup>, 1187 cm<sup>&#x02212;1</sup>, and 1101 cm<sup>&#x02212;1</sup> positions. Mucin peaks showed deviation from their positions apparently due to its binding to BaSO<sub>3</sub> particles. The presence of characteristic peaks for BaSO<sub>3</sub> particle as well as for mucin indicates positive adhesion of BaSO<sub>3</sub> particles to mucin.</p><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f011">Figure 11</xref>c shows the spectrum for free BaCO<sub>3</sub> particles, free mucin, and BaCO<sub>3</sub>-mucin complex. BaCO<sub>3</sub> particles showed 4 characteristic peaks as described in the earlier <xref ref-type="sec" rid="sec3dot1dot1-pharmaceutics-12-00710">Section 3.1.1</xref>. Mucin-adhered BaCO<sub>3</sub> particles demonstrated 9 distinctive peaks. Mucin characteristic peaks at 3279 cm<sup>&#x02212;1</sup>, 1634 cm<sup>&#x02212;1</sup>, 1549 cm<sup>&#x02212;1</sup>, 1232 cm<sup>&#x02212;1</sup>, and 1115 cm<sup>&#x02212;1</sup> were found, respectively, at 3384 cm<sup>&#x02212;1</sup>, 1645 cm<sup>&#x02212;1</sup>, 1555 cm<sup>&#x02212;1</sup>, 1213 cm<sup>&#x02212;1</sup>, and 1121 cm<sup>&#x02212;1</sup> positions in mucin-adhered BaCO<sub>3</sub> particles. The presence of characteristic peaks for BaCO<sub>3</sub> particles and mucin indicates positive adhesion of BaCO<sub>3</sub> particles to mucin.</p></sec><sec id="sec3dot5dot2-pharmaceutics-12-00710"><title>3.5.2. Quantitation of Mucin Adhesion to Particles</title><p>Percentage (%) of mucin adhesion to different Ba salt particles was calculated by measuring the protein content (mucin) precipitated out with the particles after centrifugation. Protein quantification was done by the Bradford method. The standard curve was prepared with a series of a known amount of mucin versus respective absorbance values. <xref ref-type="fig" rid="pharmaceutics-12-00710-f012">Figure 12</xref> presents Bradford assay data for mucin adhesion, where (a) shows the standard curve prepared from abs vs. known amount of mucin, whereas (b) reveals the % of adhesion to 3 different types of Ba salt particles. BaSO<sub>4</sub> particles showed highest mucin adhesion (100%), followed by BaSO<sub>3</sub> and BaCO<sub>3</sub> particles with 60&#x02013;70% of mucin adhesion.</p></sec></sec><sec id="sec3dot6-pharmaceutics-12-00710"><title>3.6. Oral Administration of Insulin-Loaded Particles to Diabetic Rats and Effect on Blood Glucose Level</title><p>Short-acting human insulin analog, Insulin Aspart (NovoRapid, Novonordisk)-loaded Ba salt particles were administrated to STZ-induced diabetic male Wister Kyoto (WKY) rats. For oral administration, particles prepared with a high concentration of reactant salts (20&#x000d7; higher than that used in original formulations) were loaded with a high dose of insulin aspart (100 IU/kg).</p><sec><title>Effect of Orally Administrated Insulin on Hyperglycemia</title><p>Insulin aspart loaded into Ba salt particles were administrated to STZ-induced diabetic male WKY rats. For oral administration, Ba salt particles prepared with 20X concentrated reactant salts (<xref rid="pharmaceutics-12-00710-t002" ref-type="table">Table 2</xref>) were loaded with a high dose of insulin aspart (NovoRapid<sup>&#x000ae;</sup>, Novo Nordisk, Bagsv&#x000e6;rd, Denmark) (100 IU/kg). <xref ref-type="fig" rid="pharmaceutics-12-00710-f013">Figure 13</xref> shows the data from control groups and treatment groups. Control groups consist of no treatment (negative control) and oral treatment of free insulin (100 IU/kg) (positive control). As expected, none of the groups showed any significant reduction of blood glucose level (<italic>p</italic> &#x0003c; 0.05) at any time point in the study. For BaSO<sub>4</sub> particles with loaded insulin, blood glucose level was significantly low compared to the baseline level in 1&#x02013;3 h (<italic>p</italic> &#x0003c; 0.05). At 4th h, the level was still low compared to the baseline level but not significant, with an ascending trend. BaCO<sub>3</sub> particles with loaded insulin showed a significant decrease of blood glucose level at 1&#x02013;2 h, although blood glucose level started to show a slight rise at 3rd h, and by 4th h, it was back to the baseline level. However, insulin-loaded BaSO<sub>3</sub> particles showed a reduction in blood glucose level but the reduction was not significant at 4 h.</p><p><xref ref-type="fig" rid="pharmaceutics-12-00710-f014">Figure 14</xref> shows a calculated % reduction of blood glucose level for BaSO<sub>4</sub>, BaSO<sub>3</sub>, and BaCO<sub>3</sub> loaded insulin. % reduction calculation shows a significant reduction of blood glucose level for BaSO<sub>4</sub> loaded insulin from 1&#x02013;3 h and BaCO<sub>3</sub> loaded insulin between 1&#x02013;2 h (<italic>p</italic> &#x0003c; 0.05). Again, because of inconsistency in glucose reduction pattern in different animals, % of reduction in case of BaSO<sub>3</sub> loaded insulin treatment was not significant at any point in time.</p></sec></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-12-00710"><title>4. Discussion</title><p>Oral insulin is the most attractive choice to eliminate the necessity of subcutaneous insulin therapy [<xref rid="B30-pharmaceutics-12-00710" ref-type="bibr">30</xref>]. As mentioned earlier, the most promising concept for oral insulin delivery is based on attaching the insulin molecule to a &#x0201c;cargo&#x0201d; that carries it through the GI tract. For that, the &#x0201c;cargo&#x0201d; or &#x0201c;carrier&#x0201d; itself has to pass all the criteria for an oral delivery candidate. Several papers reported polymeric nanoparticle as carriers for insulin [<xref rid="B3-pharmaceutics-12-00710" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-12-00710" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-12-00710" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-12-00710" ref-type="bibr">6</xref>]. The concept of complexing insulin molecules with inorganic salt particles based on ionic interactions is a relatively new one, having enormous potential [<xref rid="B22-pharmaceutics-12-00710" ref-type="bibr">22</xref>]. Ba salt particles (BaSO<sub>4</sub>, BaSO<sub>3,</sub> and BaCO<sub>3</sub>) have both positive and negative charged domains conferred, respectively, by cations (Ba<sup>2+</sup>) and anions (SO<sub>4</sub><sup>2&#x02212;</sup>, SO<sub>3</sub><sup>2&#x02212;</sup>, and CO<sub>3</sub><sup>2&#x02212;</sup>). Due to heterogeneous charge distribution, these particles are capable of binding peptide molecules like insulin through electrostatic interactions. The target protein molecule here is insulin (5.8 kDa) which also has localized surface charges either positive or negative at basic or acidic pH. These surface charges of insulin likely allowed it to electrostatically bind with either cationic or anionic charges of Ba salt particles, depending on the pH of the solution. However, the challenge was whether Ba salt particles could resist a harsh GIT environment and allow insulin molecules to pass through the intestinal wall [<xref rid="B31-pharmaceutics-12-00710" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-12-00710" ref-type="bibr">32</xref>]. This is the first study to explore the potential of Ba salt particles as oral delivery carriers for insulin.</p><p>A series of in vitro tests were carried out in GIT-mimicking conditions, before investigating the effect of orally administered insulin-loaded particles on hyperglycemia in diabetic Wister&#x02013;Kyoto rats (WKY). GIT itself is a large and complex organ system where each different chamber has its own pH and enzymatic environment. Orally administrated protein therapeutics often show poor bioavailability due to the physical as well as physiological barriers imposed by the GIT. One of the biggest challenges is protein degradation by the extreme acidic pH of the stomach. The second prominent barrier is the enzymatic degradation in both the stomach and intestine. Even after successfully bypassing the stomach pH and enzymatic action, the protein-loaded particles or the released proteins are supposed to encounter mucin of the GI lining [<xref rid="B33-pharmaceutics-12-00710" ref-type="bibr">33</xref>], prior to crossing the epithelium either via transcellular or paracellular route to reach the blood circulation.</p><sec id="sec4dot1-pharmaceutics-12-00710"><title>4.1. Characterization and Morphological Screening of Empty Ba Salt Particles</title><p>Three different Ba salt particles were characterized with FTIR to identify the functional groups of the respective particles, and EDX to detect the various elements present in those particles, thus confirming the identity of each particle type.</p></sec><sec id="sec4dot2-pharmaceutics-12-00710"><title>4.2. Particle Stability Assessment</title><p>Particle stability study was important to understand how efficiently Ba salt particles could resist harsh pHs, and thus, predict which of the Ba salt particles among BaSO<sub>4</sub>, BaSO<sub>3</sub>, and BaCO<sub>3</sub> would show the highest potential as an oral carrier. Successful oral delivery can only take place if the formulations are resistant enough in fluctuating stomach pH. Another important factor in oral delivery is stomach and intestinal residence time. Depending on the particle properties, the residence time inside the gut could vary from 20 min to 3 h [<xref rid="B34-pharmaceutics-12-00710" ref-type="bibr">34</xref>]. An ideal oral delivery carrier must be resistant to both basic and acidic pHs within that time-frame. The stomach has fluctuating pH which can vary from pH 1.7 to 4.7 [<xref rid="B35-pharmaceutics-12-00710" ref-type="bibr">35</xref>], whereas intestinal pH is around 6&#x02013;8 [<xref rid="B35-pharmaceutics-12-00710" ref-type="bibr">35</xref>].</p><p>In vitro tests were done to see whether the particles are capable of sustaining in a wide range of pHs over a certain period. As mentioned at the beginning, these particles are new and at the time of the study, properties were mostly unknown. It was important to check their response towards pH and enzymatic activity separately as well as combined. DMEM media composition is suitable for sustaining any biological molecules, like, proteins. At the same time, DMEM can accommodate pH change to a wide range. The particles (free and insulin bound) were exposed to DMEM prepared with a wide range of pH to study their self-resistance as well as resistance to hold a protein molecule against drastic pH change (described in <xref ref-type="sec" rid="sec4dot3-pharmaceutics-12-00710">Section 4.3</xref>). Turbidity which is measured as absorbance at 320nm increases as particle formation is accelerated and decreases as particle formation is inhibited or particle dissolution takes place. Particles were prepared at pH 7.8 and then exposed to lower pHs. The in vitro tests showed that BaSO<sub>4</sub> particles had the highest synthesis rate at pH of 7.8, as well as the best resistance at all pHs throughout the period of 3 h, followed by BaCO<sub>3</sub> and BaSO<sub>3</sub> particles. All three formulations seemed to be suitable as oral delivery carriers based on their pH resistance.</p></sec><sec id="sec4dot3-pharmaceutics-12-00710"><title>4.3. Insulin Loading Efficiency of Ba Salt Particles and Subsequent Release of Insulin from Particles at Lower pHs</title><p>The fluorometric assay was performed with a fixed amount of FITC-insulin added prior to the formation of insulin-loaded particles. The portion of the added FITC-insulin absorbed by the particles were later separated in a pellet form by centrifugation. All 3 Ba salt particles showed very good insulin loading efficiency (80&#x02013;100%). And insulin-loaded particles were found to be stable while gradually reducing pH to 5.0, with almost no release of insulin from the complex. At pH &#x0003c; 5 different degrees of insulin release were observed. Insulin release from BaSO<sub>4</sub> particles was 30% even in very harsh acidic pH, implying that this particular nano-insulin formulation would be stable inside the stomach regardless of fed or fasting state. However, BaSO<sub>3</sub> and BaCO<sub>3</sub> particles with loaded insulin showed almost 80&#x02013;100% release in acidic pH of nearly 1.0.</p><p>The capability of the Ba salt particles in protecting protein molecules was further assessed using albumin protein against different pHs and enzymatic effects. The data generated with albumin has been presented in supplementary figures (<xref ref-type="app" rid="app1-pharmaceutics-12-00710">Supplementary Figures S2&#x02013;S4</xref>) and discussed in detail.</p></sec><sec id="sec4dot4-pharmaceutics-12-00710"><title>4.4. Morphological Analysis of Ba Salt Particle by FE-SEM</title><p>FE-SEM image analysis confirmed the formation of Ba salt particles and revealed their morphology with regards to size, shape, and aggregation pattern. The images also showed the morphological changes of particle clusters while being loaded with insulin, confirming successful insulin loading of the particles. <xref ref-type="app" rid="app1-pharmaceutics-12-00710">Supplementary Figures S5 and S6</xref> are added with higher resolution micrographs, demonstrating in detail the morphological changes of BaSO<sub>4</sub> particles owing to insulin binding.</p></sec><sec id="sec4dot5-pharmaceutics-12-00710"><title>4.5. Assessment of Mucin Adhesion to Ba Salt Particles</title><p>Mucin of GI lining is considered as the primary barrier for any molecule to cross the intestinal lining and reach the systemic circulation. Indeed, secreted mucin along with the contents of the gut creates an intestinal fluid environment [<xref rid="B36-pharmaceutics-12-00710" ref-type="bibr">36</xref>]. Therefore, orally delivered insulin-loaded Ba salt particles will be in contact with mucin while crossing the intestinal lining. In vitro tests were done to predict whether the particles would be capable of crossing the intestinal lining. Particle adhesion to mucin was analyzed with FT-IR and Bradford protein assay kit, with FT-IR bands showing characteristic peaks for both Ba salts particle and mucin, and the protein assay reconfirming mucin adhesion to the particles quantitatively. All three Ba salt particles were found to have high mucin adhesion (60&#x02013;100%).</p></sec><sec id="sec4dot6-pharmaceutics-12-00710"><title>4.6. Effect of Orally Administrated Nano-Insulin on Hyperglycemia</title><p>For oral delivery, particle formulations were prepared in 20&#x000d7; concentrated form to efficiently load high insulin (100 IU/kg) dose. All three formulations of Ba salt particles with loaded insulin showed a significant reduction in blood glucose levels. The effect generated during oral administration of insulin-loaded particles was surprisingly similar to the effect noticed for subcutaneous delivery of commercial human insulin aspart, only lasting 4&#x02013;5 h with a maximum drop in blood glucose level during 2&#x02013;3 h. The onset of the action on hyperglycemia started at 1 h for the oral nano-insulin formulation, which could be due to the required transport time for insulin-loaded particles to reach the blood stream. The percentage of reduction of blood glucose level in comparison to the baseline level showed the maximum reduction below 50% at any time point for all 3 Ba salt particles. The newly designed Ba salt/Insulin showed a visible significant effect on hyperglycemia at doses of 100 IU/Kg and % reduction in blood glucose is less than 50%.</p><p>In vitro insulin loading and mucin adhesion profile were promising from all three Ba salt particles, however, in vitro stability and protection from pH and enzymatic activity data showed stronger protection from BaSO<sub>4</sub> and BaCO<sub>3</sub> particles towards protein molecule compared to BaSO<sub>3</sub> particle. In vivo activity in diabetic rats also reflected that. Although the BaSO<sub>3</sub> particle also successfully reduced blood glucose levels, there were fluctuations and inconsistencies in the reduction pattern between the animals which ultimately affected the significance of the finding. Notably, this inconsistency was also observed for the other two particles in a lower dose of insulin (50 IU/kg, data not shown here). The authors believe BaSO<sub>3</sub> loaded insulin might show a significant and consistent reduction of blood glucose at much higher doses. In summary, BaSO<sub>3</sub> loaded insulin is less efficient compared to BaSO<sub>4</sub> and BaCO<sub>3</sub> particle loaded oral insulin. However, there is plenty of room for improvement for these formulations.</p><p>A common problem with potential oral insulin formulations from the literature is the low bioavailability and requirement for very high doses [<xref rid="B6-pharmaceutics-12-00710" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-12-00710" ref-type="bibr">7</xref>,<xref rid="B37-pharmaceutics-12-00710" ref-type="bibr">37</xref>]. This is because of degradation in the GI tract and low percentage of intestinal crossing mainly. The onset, duration of action, and maximum reduction of blood glucose level vary a lot from formulation to formulation due to properties and diversified mechanism of action of the particle or system used as DDS for insulin molecule. Wu et.al. reported, insulin loaded PLGA/RS nanoparticles (50 IU/kg) showed a slow decrease after a lag phase of 4 h with no visible effect. The maximum blood glucose reduction was in 10 h (32%) and the effect lasted for 24 h [<xref rid="B6-pharmaceutics-12-00710" ref-type="bibr">6</xref>]. Pan et al. (2002) reported the effectiveness of positively charged CS-NP that was bound to insulin at doses 21 IU/kg and hypoglycemia prolonged for 15 h. There was no reporting of % decrease of blood glucose level [<xref rid="B7-pharmaceutics-12-00710" ref-type="bibr">7</xref>]. Another nanoparticle (NP) loaded insulin system composed of chitosan (CS) and poly(g-glutamic acid) reported an extended period of activity of insulin aspart when loaded in NP. NP loaded insulin aspart was given orally in a similar manner to Ba salt insulin administration reported in this paper. However, the effect was observed as peak-less prolonged reduction of blood glucose. The formulation loaded with insulin aspart, which is originally a short-acting human insulin analog. Interestingly in NP loaded form oral administration of it showed an effect similar to subcutaneous intermediate-acting formulations available in the market. The effect was an observer at doses of 30 IU/kg and reduction of blood glucose level was never more than 30&#x02013;40% [<xref rid="B37-pharmaceutics-12-00710" ref-type="bibr">37</xref>].</p><p>There could be several factors involved that can influence any nanoparticle-mediated insulin formulation. In general nanoparticle binding towards protein is effected/influenced by surface charge, crystallinity, size of nanoparticle as well as insulin molecule. On the other hand, oral delivery of nanoparticle loaded insulin depends on size, lipophilicity, surface charge, and resistance of the carrier molecule. The reported Ba salt insulin formulations are at an early stage. As new formulations, they are in vivo profile of GI transport and activity in the blood are unknown. Although, quick onset with the same duration of action as native insulin aspart indicates a unique in vivo profile. The formulations are under study for their details on in vivo mechanisms of action and improvement of pharmacokinetic parameters at present.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-12-00710"><title>5. Conclusions</title><p>As a novel group of oral macromolecular drug delivery system, Ba salt particles, in particular, BaSO<sub>4</sub> and BaCO<sub>3</sub> look very promising. In vitro tests on binding, resistance and characterization have shown that the particles can bind protein therapeutics like insulin efficiently. In vivo study on rats has proven their effectiveness in managing hyperglycemia when given orally. Novel nano-insulin, i.e., Ba salt particle-loaded insulin aspart (oral) has a similar effect on blood glucose level as the original insulin aspart subcutaneous formulation in higher doses. Therefore, the developed oral formulations could be an attractive alternative to subcutaneous ones in the future.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work has been partially supported by a seed grant from Health &#x00026; Wellbeing Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University Malaysia. This research received no external funding.</p></ack><app-group><app id="app1-pharmaceutics-12-00710"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/1999-4923/12/8/710/s1">https://www.mdpi.com/1999-4923/12/8/710/s1</uri>, supplementary Figure S1: Standard curve generated with data from free FITC-Insulin amount vs. abs; supplementary Figures S2&#x02013;S4: A set of supplementary data demonstrating binding affinity of albumin as a model protein to three different Ba salt particles and resistance of the particle-bound albumin to various acidic pHs and enzymatic digestion; Figures S5 and S6: Higher-resolution micrographs describing the morphological changes due to insulin binding have been included in supplementary.</p><supplementary-material content-type="local-data" id="pharmaceutics-12-00710-s001"><media xlink:href="pharmaceutics-12-00710-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>R.Z. performed all the test experiments, analyzed the data and prepared the initial draft of the manuscript, M.E.K. helped to collect the data in animal experiments, I.O. and A.Z. provided guidance as co-supervisors and E.H.C. secured the funding, originally designed the entire project, designed the methodology and edited the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>NP = nanoparticle: Ba salt = Barium salt, BaSO<sub>4</sub> = Barium Sulfate; BaSO<sub>3</sub> = Barium Sulfite; BaCO<sub>3</sub> = Barium Carbonate; GIT = gastro-intestinal tract; AA = amino acid; DDS = drug delivery system, SC = subcutaneous; STZ = streptozotocin; IP = intraperitoneal; WKY rats = Wister&#x02013;Kyoto rats; FT-IR = Fourier Transform Infrared Spectroscopy; DMEM = Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium; FITC = fluorescein isothiocyanate; EDX = elemental analysis of particle by energy dispersive X-ray spectroscopy; FE-SEM = Field Emission Scanning Electron Microscope.</p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-12-00710"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>R.</given-names></name><name><surname>Islam</surname><given-names>R.A.</given-names></name><name><surname>Ibnat</surname><given-names>N.</given-names></name><name><surname>Othman</surname><given-names>I.</given-names></name><name><surname>Zaini.</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>C.Y.</given-names></name><name><surname>Chowdhury</surname><given-names>E.H.</given-names></name></person-group><article-title>Current strategies in extending half-lives of therapeutic proteins</article-title><source>J. Control. Release</source><year>2019</year><volume>30</volume><fpage>176</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.02.016</pub-id><?supplied-pmid 30849445?><pub-id pub-id-type="pmid">30849445</pub-id></element-citation></ref><ref id="B2-pharmaceutics-12-00710"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curto</surname><given-names>M.D.D.</given-names></name><name><surname>Maroni</surname><given-names>A.</given-names></name><name><surname>Palugan</surname><given-names>L.</given-names></name><name><surname>Zema</surname><given-names>L.</given-names></name><name><surname>Gazzaniga</surname><given-names>A.</given-names></name><name><surname>Sangalli</surname><given-names>M.E.</given-names></name></person-group><article-title>Oral Delivery System for Two-pulse Colonic Release of Protein. Drugs and Protease Inhibitor/Absorption Enhancer Compounds</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>3251</fpage><lpage>3259</lpage><pub-id pub-id-type="doi">10.1002/jps.22560</pub-id><?supplied-pmid 21465487?><pub-id pub-id-type="pmid">21465487</pub-id></element-citation></ref><ref id="B3-pharmaceutics-12-00710"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>R.</given-names></name><name><surname>Othman</surname><given-names>I.</given-names></name><name><surname>Chowdhury</surname><given-names>E.H.</given-names></name></person-group><article-title>Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>6167</fpage><lpage>6191</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160720145328</pub-id><?supplied-pmid 27510479?><pub-id pub-id-type="pmid">27510479</pub-id></element-citation></ref><ref id="B4-pharmaceutics-12-00710"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiowitz</surname><given-names>E.</given-names></name><name><surname>Jacob</surname><given-names>J.S.</given-names></name><name><surname>Jong</surname><given-names>Y.S.</given-names></name><name><surname>Carino</surname><given-names>G.P.</given-names></name><name><surname>Chickering</surname><given-names>D.E.</given-names></name><name><surname>Chaturvedi</surname><given-names>P.</given-names></name><name><surname>Santos</surname><given-names>C.A.</given-names></name><name><surname>Vijayaraghvan</surname><given-names>K.</given-names></name><name><surname>Montgomery</surname><given-names>S.</given-names></name><name><surname>Bassett</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Biologically erodable microspheres as potential oral drug delivery systems</article-title><source>Nature</source><year>1997</year><volume>386</volume><fpage>410</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/386410a0</pub-id><?supplied-pmid 9121559?><pub-id pub-id-type="pmid">9121559</pub-id></element-citation></ref><ref id="B5-pharmaceutics-12-00710"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ensign</surname><given-names>L.M.</given-names></name><name><surname>Cone</surname><given-names>R.</given-names></name><name><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers</article-title><source>Adv. Drug Deliv. Rev.</source><year>2012</year><volume>64</volume><fpage>557</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2011.12.009</pub-id><pub-id pub-id-type="pmid">22212900</pub-id></element-citation></ref><ref id="B6-pharmaceutics-12-00710"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.M.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>X.D.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Ling</surname><given-names>L.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>K.Q.</given-names></name><name><surname>Zhang</surname><given-names>L.J.</given-names></name></person-group><article-title>HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>425</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.12.055</pub-id><pub-id pub-id-type="pmid">22248666</pub-id></element-citation></ref><ref id="B7-pharmaceutics-12-00710"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.J.</given-names></name><name><surname>Zhao</surname><given-names>H.Y.</given-names></name><name><surname>Zheng</surname><given-names>J.M.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Hao</surname><given-names>J.S.</given-names></name></person-group><article-title>Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo</article-title><source>Int. J. Pharm.</source><year>2002</year><volume>249</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(02)00486-6</pub-id><pub-id pub-id-type="pmid">12433442</pub-id></element-citation></ref><ref id="B8-pharmaceutics-12-00710"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Lim</surname><given-names>T.M.</given-names></name><name><surname>Lim</surname><given-names>L.Y.</given-names></name></person-group><article-title>Pharmacological activity of peroral chitosan- insulin nanoparticles in diabetic rats</article-title><source>Int. J. Pharm.</source><year>2005</year><volume>293</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2004.12.025</pub-id><pub-id pub-id-type="pmid">15778065</pub-id></element-citation></ref><ref id="B9-pharmaceutics-12-00710"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso-Sande</surname><given-names>M.</given-names></name><name><surname>Teijeiro-Osorio</surname><given-names>D.</given-names></name><name><surname>Remu&#x000f1;&#x000e1;n-L&#x000f3;pez</surname><given-names>C.</given-names></name><name><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Glucomannan, a promising polysaccharide for biopharmaceutical purposes</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2009</year><volume>72</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2008.02.005</pub-id><pub-id pub-id-type="pmid">18511246</pub-id></element-citation></ref><ref id="B10-pharmaceutics-12-00710"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Des Rieux</surname><given-names>A.</given-names></name><name><surname>Fievez</surname><given-names>V.</given-names></name><name><surname>Garinot</surname><given-names>M.</given-names></name><name><surname>Schneider</surname><given-names>Y.J.</given-names></name><name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name></person-group><article-title>Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach</article-title><source>J. Control. Release</source><year>2006</year><volume>116</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.08.013</pub-id><pub-id pub-id-type="pmid">17050027</pub-id></element-citation></ref><ref id="B11-pharmaceutics-12-00710"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>C.</given-names></name><name><surname>Harpe</surname><given-names>V.</given-names></name></person-group><article-title>Digestive system structure and function</article-title><source>Laboratory Manual for Anatomy and Physiology</source><edition>4th ed.</edition><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2011</year><fpage>570</fpage></element-citation></ref><ref id="B12-pharmaceutics-12-00710"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Banga</surname><given-names>A.K.</given-names></name></person-group><article-title>Oral Delivery of Peptide and Protein Drugs</article-title><source>Therapeutic Peptides and Proteins Formulation, Processing, and Delivery Systems</source><edition>2nd ed.</edition><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FA, USA</publisher-loc><publisher-name>Taylor &#x00026; Francis Group</publisher-name><publisher-loc>Park Drive, UK</publisher-loc><year>2006</year><fpage>229</fpage><lpage>250</lpage></element-citation></ref><ref id="B13-pharmaceutics-12-00710"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauland</surname><given-names>A.H.</given-names></name><name><surname>Guggi</surname><given-names>D.</given-names></name><name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A.</given-names></name></person-group><article-title>Oral insulin delivery: The potential of thiolated chitosan-insulin tablets on nondiabetic rats</article-title><source>J. Control. Release</source><year>2004</year><volume>95</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2003.12.017</pub-id><?supplied-pmid 15023465?><pub-id pub-id-type="pmid">15023465</pub-id></element-citation></ref><ref id="B14-pharmaceutics-12-00710"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molero</surname><given-names>J.E.</given-names></name><name><surname>Aleck</surname><given-names>K.</given-names></name><name><surname>Sinha</surname><given-names>M.K.</given-names></name><name><surname>Brownscheidle</surname><given-names>C.M.</given-names></name><name><surname>Shapiro</surname><given-names>L.J.</given-names></name><name><surname>Sperling</surname><given-names>M.A.</given-names></name></person-group><article-title>Orally administered liposome entrapped insulin in diabetic animals</article-title><source>Horm. Res.</source><year>1982</year><volume>16</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1159/000179509</pub-id><?supplied-pmid 6751980?><pub-id pub-id-type="pmid">6751980</pub-id></element-citation></ref><ref id="B15-pharmaceutics-12-00710"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanov</surname><given-names>A.V.</given-names></name><name><surname>Kononenko</surname><given-names>N.I.</given-names></name><name><surname>Lishko</surname><given-names>V.K.</given-names></name><name><surname>Shevchenko</surname><given-names>A.V.</given-names></name></person-group><article-title>Effect of liposomally entrapped insulin administered per os on the blood sugar level in normal and experimentally diabetic rats</article-title><source>Ukr. Biokhim. Zh.</source><year>1980</year><volume>52</volume><fpage>497</fpage><lpage>500</lpage><?supplied-pmid 7010733?><pub-id pub-id-type="pmid">7010733</pub-id></element-citation></ref><ref id="B16-pharmaceutics-12-00710"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halberg</surname><given-names>I.</given-names></name><name><surname>Lyby</surname><given-names>K.</given-names></name><name><surname>Wassermann</surname><given-names>K.</given-names></name><name><surname>Heise</surname><given-names>T.</given-names></name><name><surname>Zijlstra</surname><given-names>E.</given-names></name><name><surname>Plum-M&#x000f6;rschel</surname><given-names>L.</given-names></name></person-group><article-title>Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: A randomised, double-blind, phase 2 trial</article-title><source>Lancet. Diabetes Endocrinol.</source><year>2018</year><volume>18</volume><fpage>30372</fpage><lpage>30373</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(18)30372-3</pub-id></element-citation></ref><ref id="B17-pharmaceutics-12-00710"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>D.J.</given-names></name></person-group><article-title>Advances in oral peptide therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>19</volume><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0053-0</pub-id><pub-id pub-id-type="pmid">31848464</pub-id></element-citation></ref><ref id="B18-pharmaceutics-12-00710"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>J.M.</given-names></name><name><surname>Lautz</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>L.M.</given-names></name><name><surname>Williams</surname><given-names>P.E.</given-names></name><name><surname>Reddy</surname><given-names>P.</given-names></name><name><surname>Cherrington</surname><given-names>A.D.</given-names></name></person-group><article-title>Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs</article-title><source>Diabetes Obes. Metab.</source><year>2019</year><volume>21</volume><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/dom.13498</pub-id><pub-id pub-id-type="pmid">30095210</pub-id></element-citation></ref><ref id="B19-pharmaceutics-12-00710"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbit</surname><given-names>E.</given-names></name><name><surname>Kidron</surname><given-names>M.</given-names></name></person-group><article-title>Oral insulin delivery in a physiologic context: Review</article-title><source>J. Diabetes Sci. Technol.</source><year>2017</year><volume>11</volume><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1177/1932296817691303</pub-id><?supplied-pmid 28654313?><pub-id pub-id-type="pmid">28654313</pub-id></element-citation></ref><ref id="B20-pharmaceutics-12-00710"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geho</surname><given-names>W.B.</given-names></name><name><surname>Rosenberg</surname><given-names>L.N.</given-names></name><name><surname>Schwartz</surname><given-names>S.L.</given-names></name><name><surname>Lau</surname><given-names>J.R.</given-names></name><name><surname>Gana</surname><given-names>T.J.</given-names></name></person-group><article-title>A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus</article-title><source>J. Diabetes Sci. Technol.</source><year>2014</year><volume>8</volume><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1177/1932296814524871</pub-id><pub-id pub-id-type="pmid">24876619</pub-id></element-citation></ref><ref id="B21-pharmaceutics-12-00710"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Othman</surname><given-names>I.</given-names></name><name><surname>Zain</surname><given-names>A.Z.M.</given-names></name></person-group><article-title>Controlled release of insulin in blood from strontium-substituted carbonate apatite complexes</article-title><source>Curr. Drug Deliv.</source><year>2015</year><volume>12</volume><fpage>210</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.2174/1567201811666140708104031</pub-id><pub-id pub-id-type="pmid">22452407</pub-id></element-citation></ref><ref id="B22-pharmaceutics-12-00710"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Busaidi</surname><given-names>H.</given-names></name><name><surname>Karim</surname><given-names>M.E.</given-names></name><name><surname>Abidin</surname><given-names>S.</given-names></name><name><surname>Tha</surname><given-names>K.K.</given-names></name><name><surname>Chowdhury</surname><given-names>E.H.</given-names></name></person-group><article-title>Magnesium Fluoride Forms Unique Protein Corona for Efficient Delivery of Doxorubicin into Breast Cancer Cells</article-title><source>Toxics</source><year>2019</year><volume>7</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3390/toxics7010010</pub-id></element-citation></ref><ref id="B23-pharmaceutics-12-00710"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakhtiar</surname><given-names>A.</given-names></name><name><surname>Kamaruzman</surname><given-names>N.I.</given-names></name><name><surname>Othman</surname><given-names>I.</given-names></name><name><surname>Zaini</surname><given-names>A.</given-names></name><name><surname>Chowdhury</surname><given-names>E.H.</given-names></name></person-group><article-title>Intracellular Delivery of p53 Gene and MAPK siRNA into Breast Cancer Cells utilizing Barium Salt Nanoparticles</article-title><source>J. Breast Cancer Res. Adv.</source><year>2017</year><volume>1</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="B24-pharmaceutics-12-00710"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sifontes</surname><given-names>&#x000c1;.B.</given-names></name><name><surname>Ca&#x000f1;izales</surname><given-names>E.</given-names></name><name><surname>Toro-Mendoza</surname><given-names>J.</given-names></name><name><surname>&#x000c1;vila</surname><given-names>E.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>P.</given-names></name><name><surname>Blas</surname><given-names>A.</given-names></name><name><surname>Delgado</surname><given-names>G.</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>B.</given-names></name><name><surname>D&#x000ed;az</surname><given-names>Y.</given-names></name><name><surname>Cruz-Barrios</surname><given-names>E.</given-names></name></person-group><article-title>Obtaining Highly Crystalline Barium Sulphate Nanoparticles via Chemical Precipitation and Quenching in Absence of Polymer Stabilizers</article-title><source>J. Nanomater.</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2015/510376</pub-id></element-citation></ref><ref id="B25-pharmaceutics-12-00710"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>V.</given-names></name><name><surname>Vimalathithan</surname><given-names>R.M.</given-names></name><name><surname>Ponnusamy</surname><given-names>V.</given-names></name></person-group><article-title>Synthesis and characterization of BaSO<sub>4</sub> nano-particles using micro emulsion technique</article-title><source>Adv. Appl. Sci. Res.</source><year>2010</year><volume>1</volume><fpage>197</fpage><lpage>204</lpage></element-citation></ref><ref id="B26-pharmaceutics-12-00710"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Sha</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Shiab</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Controllable synthesis of nanostructured BaSO<sub>4</sub> and BaSO<sub>3</sub> crystals on the basis of DMSO oxidation chemistry</article-title><source>CrystEngComm</source><year>2018</year><volume>20</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1039/C7CE01937H</pub-id></element-citation></ref><ref id="B27-pharmaceutics-12-00710"><label>27.</label><element-citation publication-type="web"><article-title>Infrared Spectroscopy (IR). Studylab</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://studylib.net/doc/10832883/infrared-spectroscopy-ir-">https://studylib.net/doc/10832883/infrared-spectroscopy-ir-</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-02">(accessed on 2 April 2020)</date-in-citation></element-citation></ref><ref id="B28-pharmaceutics-12-00710"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreedhar</surname><given-names>B.</given-names></name><name><surname>Vani</surname><given-names>C.S.</given-names></name><name><surname>Devi</surname><given-names>D.K.</given-names></name><name><surname>Rao</surname><given-names>M.B.</given-names></name><name><surname>Rambabu</surname><given-names>C.</given-names></name></person-group><article-title>Shape Controlled Synthesis of Barium Carbonate Microclusters and Nanocrystallites using Natural Polysachharide&#x02014;Gum Acacia</article-title><source>Am. J. Mater. Sci.</source><year>2012</year><volume>2</volume><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.5923/j.materials.20120201.02</pub-id></element-citation></ref><ref id="B29-pharmaceutics-12-00710"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>J.G.</given-names></name><name><surname>Soloway</surname><given-names>R.D.</given-names></name><name><surname>Martini</surname><given-names>D.K.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>G-X.</given-names></name></person-group><article-title>Influence of water on the Infrared Spectra of Mucin</article-title><source>Mikrochim. Acta</source><year>1988</year><volume>1</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/BF01205906</pub-id></element-citation></ref><ref id="B30-pharmaceutics-12-00710"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zijlstra</surname><given-names>E.</given-names></name><name><surname>Heinemann</surname><given-names>L.</given-names></name><name><surname>Plum-M&#x000f6;rschel</surname><given-names>L.</given-names></name></person-group><article-title>Oral Insulin Reloaded: A Structured Approach</article-title><source>J. Diabetes Sci. Technol.</source><year>2014</year><volume>8</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1177/1932296814529988</pub-id><pub-id pub-id-type="pmid">24876606</pub-id></element-citation></ref><ref id="B31-pharmaceutics-12-00710"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kontermann</surname><given-names>R.E.</given-names></name></person-group><article-title>Half-life extended biotherapeutics</article-title><source>Expert Opin. Biol. Ther.</source><year>2016</year><volume>16</volume><fpage>903</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1517/14712598.2016.1165661</pub-id><pub-id pub-id-type="pmid">26967759</pub-id></element-citation></ref><ref id="B32-pharmaceutics-12-00710"><label>32.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Deangelis</surname><given-names>P.L.</given-names></name></person-group><article-title>Heparosan Polymers and Methods of Making and Using Same for the Enhancement of Therapeutics, the Board of Regents of the University of Oklahoma</article-title><source>U.S. Patent</source><patent>9,603,945</patent><day>28</day><month>5</month><year>2017</year></element-citation></ref><ref id="B33-pharmaceutics-12-00710"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakhru</surname><given-names>S.H.</given-names></name><name><surname>Furtado</surname><given-names>S.</given-names></name><name><surname>Morello</surname><given-names>A.P.</given-names></name><name><surname>Mathiowitz</surname><given-names>E.</given-names></name></person-group><article-title>Oral delivery of proteins by biodegradable nanoparticles</article-title><source>Adv. Drug. Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>811</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.04.006</pub-id><pub-id pub-id-type="pmid">23608641</pub-id></element-citation></ref><ref id="B34-pharmaceutics-12-00710"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Gesenberg</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>Oral Formulations for Preclinical Studies: Principle, Design, and Development Considerations (Chapter 17)</article-title><source>Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G.G.Z.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Mantri</surname><given-names>R.V.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2017</year><fpage>455</fpage><lpage>495</lpage></element-citation></ref><ref id="B35-pharmaceutics-12-00710"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koziolek</surname><given-names>M.</given-names></name><name><surname>Grimm</surname><given-names>M.</given-names></name><name><surname>Becker</surname><given-names>D.</given-names></name><name><surname>Iordanov</surname><given-names>V.</given-names></name><name><surname>Zou</surname><given-names>H.</given-names></name><name><surname>Shimizu</surname><given-names>J.</given-names></name><name><surname>Wanke</surname><given-names>C.</given-names></name><name><surname>Garbacz</surname><given-names>G.</given-names></name><name><surname>Weitschies</surname><given-names>W.</given-names></name></person-group><article-title>Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap<sup>&#x000ae;</sup> System</article-title><source>JPDDR</source><year>2015</year><volume>104</volume><fpage>2855</fpage><lpage>2863</lpage><pub-id pub-id-type="doi">10.1002/jps.24274</pub-id></element-citation></ref><ref id="B36-pharmaceutics-12-00710"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>K.</given-names></name><name><surname>Sugiyama</surname><given-names>M.</given-names></name><name><surname>Mukai</surname><given-names>T.</given-names></name></person-group><article-title>Adhesion Properties of Lactic Acid Bacteria on Intestinal Mucin</article-title><source>Microorganisms</source><year>2016</year><volume>4</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms4030034</pub-id><?supplied-pmid 27681930?><pub-id pub-id-type="pmid">27681930</pub-id></element-citation></ref><ref id="B37-pharmaceutics-12-00710"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonaje</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>K.J.</given-names></name><name><surname>Wey</surname><given-names>S.P.</given-names></name><name><surname>Lin</surname><given-names>C.K.</given-names></name><name><surname>Yeh</surname><given-names>T.H.</given-names></name><name><surname>Nguyen</surname><given-names>H.N.</given-names></name><name><surname>Hsu</surname><given-names>C.W.</given-names></name><name><surname>Yen</surname><given-names>T.C.</given-names></name><name><surname>Juang</surname><given-names>J.H.</given-names></name><name><surname>Sung</surname><given-names>H.W.</given-names></name></person-group><article-title>Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>6849</fpage><lpage>6858</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.05.042</pub-id><?supplied-pmid 20619787?><pub-id pub-id-type="pmid">20619787</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-12-00710-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A simplified schematic representation of precipitation reaction [<xref rid="B24-pharmaceutics-12-00710" ref-type="bibr">24</xref>]. AX(soluble) + BY(soluble) = AY(precipitate) + BX(soluble)</p></caption><graphic xlink:href="pharmaceutics-12-00710-g001"/></fig><fig id="pharmaceutics-12-00710-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A simplified illustration of insulin loading into particles.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g002"/></fig><fig id="pharmaceutics-12-00710-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>FT-IR analysis of Ba salt particles. (<bold>a</bold>) Shows characteristic peaks for BaSO<sub>4</sub> particles. Characteristic peaks are detected at 2360 cm<sup>&#x02212;1</sup>, 1188 cm<sup>&#x02212;1</sup>, 1060 cm<sup>&#x02212;1</sup>, 982 cm<sup>&#x02212;1</sup>, 1635 cm<sup>&#x02212;1</sup>, 604 cm<sup>&#x02212;1</sup>, and 637 cm<sup>&#x02212;1</sup>. (<bold>b</bold>) Represents characteristic peaks for BaSO<sub>3</sub> particles at 490 cm<sup>&#x02212;1</sup>, 630 cm<sup>&#x02212;1</sup>, 912 cm<sup>&#x02212;1</sup>, and 1133 cm<sup>&#x02212;1</sup>. (<bold>c</bold>) Represents characteristic peaks for BaCO<sub>3</sub> particles at 855 cm<sup>&#x02212;1</sup>, 692 cm<sup>&#x02212;1</sup>, 1414 cm<sup>&#x02212;1</sup>, and 1059 cm<sup>&#x02212;1</sup>.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g003"/></fig><fig id="pharmaceutics-12-00710-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Element analysis of Ba salt particles. (<bold>a</bold>) The presence of Ba, S, and O elements in the sample for BaSO<sub>4</sub> particles. (<bold>b</bold>) Presence of Ba, S, and O elements in the sample for BaSO<sub>3</sub> particles. (<bold>c</bold>) The presence of Ba, C, and O elements in the sample for BaCO<sub>3</sub> particles.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g004"/></fig><fig id="pharmaceutics-12-00710-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Dissolution of profiles of three different Ba salt particles upon exposure to a wide range of pHs (pH 7.78&#x02013;pH 1.78) over a time period of 3 h. Ba salt particles were synthesized at pH 7.78 and exposed to different pHs to observe particle dissolution. (<bold>a</bold>), (<bold>b</bold>) and (<bold>c</bold>) plots data from 1 h, 2 h and 3 h respectively.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g005"/></fig><fig id="pharmaceutics-12-00710-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Measurement of insulin binding affinity towards Ba salt particles. The efficiency of FITC-insulin association with the particles (%loading) at pH 7.78 and subsequent release (%release) of FITC-insulin after exposure of the insulin-particle complexes to a range of pHs were calculated from fluorescein intensity of FITC-insulin loaded into Ba salt particle. (<bold>a</bold>) Shows % loading of FITC-insulin into Ba salt particle (BaSO<sub>4</sub>, BaSO<sub>3,</sub> and BaCO<sub>3</sub>). (<bold>b</bold>) Presents the formula for calculation of %loading and %release of insulin, whereas (<bold>c</bold>) demonstrates the data pertaining to % release of FITC-insulin at lower pHs (pH 7.14&#x02013;pH 1.78).</p></caption><graphic xlink:href="pharmaceutics-12-00710-g006"/></fig><fig id="pharmaceutics-12-00710-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>FE-SEM pictures of Ba salt particles. (<bold>a</bold>) BaSO<sub>4</sub> particles show distinctive irregular, oval to hollow rounder shape with particle size between 30&#x02013;150 nm; (<bold>b</bold>) BaSO<sub>3</sub> particles form innate baseball shape particles of a rough surface with particle size between 15&#x02013;270 nm; (<bold>c</bold>) BaCO<sub>3</sub> particles form rod shape particles with particle size between 50&#x02013;500 nm.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g007"/></fig><fig id="pharmaceutics-12-00710-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>FE-SEM images of BaSO<sub>4</sub> particles (free and loaded with insulin).</p></caption><graphic xlink:href="pharmaceutics-12-00710-g008"/></fig><fig id="pharmaceutics-12-00710-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Images of empty and insulin-loaded BaSO<sub>3</sub> particles. (<bold>a</bold>) Empty BaSO<sub>3</sub> particles look more aggregated. (<bold>b</bold>) Insulin-loaded BaSO<sub>3</sub> particles prepared with 50 &#x000b5;g of insulin form distinctive oval-shaped separate clusters. Pictures were taken at 2.0 kV.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g009"/></fig><fig id="pharmaceutics-12-00710-f010" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Images from free and insulin-loaded BaCO<sub>3</sub> particles. (<bold>a</bold>) Empty BaCO<sub>3</sub> particles look more aggregated. (<bold>b</bold>) Insulin-loaded BaCO<sub>3</sub> s form distinctive rod/needle-shaped separate clusters. Pictures were taken at 2.0 kV.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g010"/></fig><fig id="pharmaceutics-12-00710-f011" orientation="portrait" position="float"><label>Figure 11</label><caption><p>FT-IR spectrum showing mucin adhesion to three different Ba salt particles. Particle only, mucin only, and particles adhered to mucin were analyzed with FT-IR. (<bold>a</bold>) The spectrum for BaSO<sub>4</sub> particle only, free mucin, and BaSO<sub>4</sub>-mucin complex. (<bold>b</bold>) The spectrum for BaSO<sub>3</sub> particle only, free mucin, and BaSO<sub>3</sub>-mucin complex. (<bold>c</bold>) The spectrum for BaCO<sub>3</sub> particle only, free mucin, and BaCO<sub>3</sub>-mucin complex.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g011a"/><graphic xlink:href="pharmaceutics-12-00710-g011b"/></fig><fig id="pharmaceutics-12-00710-f012" orientation="portrait" position="float"><label>Figure 12</label><caption><p>Mucin adhesion efficiency of Ba salt particles. (<bold>a</bold>) The standard curve with absorption vs. known amounts was obtained from solutions of different amounts of mucin (25&#x02013;600 &#x000b5;g). (<bold>b</bold>) % mucin adhesion of particles was calculated from the absorbance of an unknown sample. BaSO<sub>4</sub> -M: Mucin adhered to BaSO<sub>4</sub> particles; BaSO<sub>3</sub> -M: Mucin adhered to BaSO<sub>3</sub> particles; BaCO<sub>3</sub> -M: Mucin adhered to BaCO<sub>3</sub> particles. Absorbance was read at 595 nm.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g012a"/><graphic xlink:href="pharmaceutics-12-00710-g012b"/></fig><fig id="pharmaceutics-12-00710-f013" orientation="portrait" position="float"><label>Figure 13</label><caption><p>Oral delivery of free insulin and particle loaded insulin effect on hyperglycemia. The group of STZ-induced diabetic rats without any treatment was taken as a negative control, whereas the group of STZ-induced diabetic rats treated with free insulin was considered as a positive control. 3 different treatment groups of diabetic rats were orally given Insulin aspart-loaded particles of BaSO<sub>4</sub>, BaSO<sub>3,</sub> and BaCO<sub>3.</sub> Each control and treatment groups have 3 animals per group. The baseline blood glucose level was read before the treatment. All 3 insulin-loaded Ba salt formulations showed a reduction in blood glucose level within 1 h of the oral administration. Mean value of (&#x000b1;standard deviation) was plotted for BaSO<sub>4</sub>, BaSO<sub>3</sub>, and BaCO<sub>3</sub> loaded with Insulin aspart (100 IU/kg) (<italic>p</italic> &#x0003c; 0.05)<bold>.</bold> For BaSO<sub>4</sub> particles with loaded insulin, blood glucose level was significantly low compared to the baseline level in 1&#x02013;3 h (<italic>p</italic> &#x0003c; 0.05). At 4th h, the level was still low compared to the baseline level but not significant, with an ascending trend. BaCO<sub>3</sub> particles with loaded insulin showed a significant decrease of blood glucose level at 1&#x02013;2 h, although blood glucose level started to show a slight rise at 3rd h, and by the 4th h, it was back to the baseline level. However, insulin-loaded BaSO<sub>3</sub> particles showed a reduction in blood glucose level but the reduction was not significant at 4 h.</p></caption><graphic xlink:href="pharmaceutics-12-00710-g013"/></fig><fig id="pharmaceutics-12-00710-f014" orientation="portrait" position="float"><label>Figure 14</label><caption><p>Oral administration of insulin-loaded Ba salt particles. Animals were fed with Ba salt particles with loaded insulin (100 IU/kg). Each control and treatment groups have 3 animals per group. The baseline blood glucose level was read before the treatment. % of reduction of blood glucose level at different time points. The blood glucose level at &#x0201c;0&#x0201d; h is the baseline blood glucose reading taken right before oral treatment with insulin-loaded particles. The mean value of (&#x000b1; standard deviation) was plotted for BaSO<sub>4</sub>, BaSO<sub>3</sub>, and BaCO<sub>3</sub> loaded with Insulin aspart (100 IU/kg). A significant % reduction was observed for BaSO<sub>4</sub> loaded insulin (1&#x02013;3 h) and BaCO<sub>3</sub> loaded insulin (1&#x02013;2 h) (<italic>p</italic> &#x0003c; 0.05)<bold>.</bold></p></caption><graphic xlink:href="pharmaceutics-12-00710-g014"/></fig><table-wrap id="pharmaceutics-12-00710-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00710-t001_Table 1</object-id><label>Table 1</label><caption><p>Formulations of three different Ba salt particles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Salt B</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ba Salt Particles</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salt A(1M BaCl<sub>2,</sub> 5 &#x000b5;L)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>4</sub> (2 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>4</sub>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>3</sub> (2 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>3</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1M Na<sub>2</sub>CO<sub>3</sub>(2 &#x000b5;L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BaCO<sub>3</sub>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">20&#x000d7; concentrated Ba particle formulations prepared for in vivo use </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1M Na<sub>2</sub>CO<sub>3</sub>(40 &#x000b5;L)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>BaCO<sub>3</sub></bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Salt B</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ba salt particles</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Salt A (1M BaCl<sub>2</sub> 100 &#x000b5;L)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>4</sub> (40 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>4</sub>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>3</sub> (40 &#x000b5;L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BaSO<sub>3</sub></td></tr></tbody></table><table-wrap-foot><fn><p>&#x000d7; all the reactants were prepared from 1M stock solution.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-12-00710-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-12-00710-t002_Table 2</object-id><label>Table 2</label><caption><p>Ba salt particle formulations loaded with insulin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Salt B</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Insulin</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Salt A(1 M BaCl<sub>2</sub> 5 &#x000b5;L)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>4</sub> (2 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">FITC-Insulin(2 mg/mL,1&#x02013;25 &#x000b5;L)/Insulin Aspart (1&#x02013;5 IU/kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>4</sub>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>3</sub> (2 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">FITC-Insulin(2 mg/mL,1&#x02013;25 &#x000b5;L)/Insulin Aspart (1&#x02013;5 IU/kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>3</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1M Na<sub>2</sub>CO<sub>3</sub>(2 &#x000b5;L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FITC-Insulin(2 mg/mL,1&#x02013;25 &#x000b5;L)/Insulin Aspart (1&#x02013;5 IU/kg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BaCO<sub>3</sub></td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">20&#x000d7; concentrated Ba particle formulations loaded with Insulin Aspart prepared for in vivo use</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Salt B</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Insulin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Salt (1 M BaCl<sub>2</sub> 100 &#x000b5;L)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>4</sub> (40 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">Insulin Aspart (100 IU/kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>4</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1M Na<sub>2</sub>SO<sub>3</sub> (40 &#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">Insulin Aspart (100 IU/kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">BaSO<sub>3</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1M Na<sub>2</sub>CO<sub>3</sub>(40 &#x000b5;L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insulin Aspart (100 IU/kg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BaCO<sub>3</sub></td></tr></tbody></table></table-wrap></floats-group></article>